ArticleInfectious agents and cancer2026
Inhibition of death-ligand-induced apoptosis in Epstein-Barr virus-encoded small RNAs-expressing human T-cell line.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn chronic active Epstein-Barr virus (EBV) (CAEBV) disease, EBV infects T or natural killer (NK) cells, and patients frequently exhibit a broad spectrum of EBV-associated T/NK-cell lymphoproliferative disorders including polyclonal, oligoclonal, and monoclonal proliferation, and sometimes develop EBV-positive NK/T-cell lymphoma. In the development of malignant tumor, the acquisition of the ability of resisting cell death is an important factor.
methodsWe have introduced a plasmid containing the coding sequences of EBV-encoded small RNAs (EBERs) or latent membrane protein (LMP) 1 into human T-lymphocyte virus-I-negative human T-cell lines using an expression plasmid vector harboring EBV nuclear antigen 1 and established stable transformants. Using these stable transformants, we evaluated the change of sensitivity to apoptosis induction with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L or soluble FasL (sFasL) in T cell lines with the expression of latent EBV genes, EBERs or LMP1.
resultsAmong five human T-cell lines examined, Jurkat was the most sensitive cell line to the induction of cell death with both of Apo2L and sFasL, and the stable transformants of Jurkat cells expressing EBERs (Jurkat/E6) or LMP1 (Jurkat/L) exhibited the resistance to the cell death induced with both of Apo2L and sFasL. In Jurkat/E6 cells, the expression of cFLIPS, which blocks procaspase-8 activation and apoptosis, was a little enhanced, and in Jurkat/L cells, the phosphorylation of IκBα was constitutively upregulated, which leads to cell survival signals. Furthermore, Jurkat/E6 cells with decrease expression of EBERs after 6-months-culture without plasmid selection antibiotics exhibited the restored sensitivity to both death ligands-induced apoptosis in part, although Jurkat/L cells with decreased expression of LMP1 did not.
conclusionEBERs would be responsible for the induction of resistance to death-ligand-induced apoptosis, and might contribute to the development of EBV-positive lymphoma of non-B-cell lineage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.